Lung Cancer: Targets and Therapy

ISSN: 1179-2728

Archive: Volume 15, 2024

Expert Opinion

Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

Ou SI, Le X, Nagasaka M, Reungwetwattana T, Ahn MJ, Lim DW, Santos ES, Shum E, Lau SC, Lee JB, Calles A, Wu F, Lopes G, Sriuranpong V, Tanizaki J, Horinouchi H, Garassino MC, Popat S, Besse B, Rosell R, Soo RA

Lung Cancer: Targets and Therapy 2024, 15:87-114

Published Date: 22 June 2024

Commentary

ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?

Lee JB, Ou SI

Lung Cancer: Targets and Therapy 2024, 15:81-85

Published Date: 25 May 2024

Commentary

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

Lee ATM, Ou SI

Lung Cancer: Targets and Therapy 2024, 15:75-80

Published Date: 23 May 2024

Commentary

“ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834)

Luo FX, Ou SI

Lung Cancer: Targets and Therapy 2024, 15:69-73

Published Date: 18 May 2024

Original Research

HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer

González-Cao M, Cai X, Bracht JWP, Han X, Yang Y, Pedraz-Valdunciel C, Morán T, García-Corbacho J, Aguilar A, Bernabé R, De Marchi P, Sussuchi da Silva L, Leal LF, Reis RM, Codony-Servat J, Jantus-Lewintre E, Molina-Vila MA, Cao P, Rosell R

Lung Cancer: Targets and Therapy 2024, 15:55-67

Published Date: 9 May 2024

Commentary